Archana S Patil, Shweta Aloshi, Yadishma Gaude, Rajashree S Masareddy
{"title":"Gastroretentive microballoons of olmesartan medoxomil: formulation and <i>in vitro-in vivo</i> evaluation.","authors":"Archana S Patil, Shweta Aloshi, Yadishma Gaude, Rajashree S Masareddy","doi":"10.1080/20415990.2025.2466418","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Olmesartan medoxomil, classified as BCS class II due to its poor water solubility, exhibits a low oral bioavailability of 28.6%.</p><p><strong>Materials and methods: </strong>Microballoons of Olmesartan medoxomil were formulated using the ionotropic gelation technique and subjected to various evaluation parameters.</p><p><strong>Results: </strong>The particles were found to be in the range of 85.11 to 312.6 µm. The prepared microballoons remained buSSoyant for more than 12 hours and showed percentage of cumulative drug release between 56.32-83.62%. <i>In vivo</i> studies showed significant reduction in Systolic blood pressure (SBP) in optimized formulation (OF).</p><p><strong>Conclusion: </strong>The formulated microballoons (hollow microspheres) emerged as a promising option for an oral gastro retentive controlled drug delivery system for Olmesartan medoxomil.</p>","PeriodicalId":22959,"journal":{"name":"Therapeutic delivery","volume":" ","pages":"1-10"},"PeriodicalIF":3.0000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20415990.2025.2466418","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Olmesartan medoxomil, classified as BCS class II due to its poor water solubility, exhibits a low oral bioavailability of 28.6%.
Materials and methods: Microballoons of Olmesartan medoxomil were formulated using the ionotropic gelation technique and subjected to various evaluation parameters.
Results: The particles were found to be in the range of 85.11 to 312.6 µm. The prepared microballoons remained buSSoyant for more than 12 hours and showed percentage of cumulative drug release between 56.32-83.62%. In vivo studies showed significant reduction in Systolic blood pressure (SBP) in optimized formulation (OF).
Conclusion: The formulated microballoons (hollow microspheres) emerged as a promising option for an oral gastro retentive controlled drug delivery system for Olmesartan medoxomil.
期刊介绍：
Delivering therapeutics in a way that is right for the patient - safe, painless, reliable, targeted, efficient and cost effective - is the fundamental aim of scientists working in this area. Correspondingly, this evolving field has already yielded a diversity of delivery methods, including injectors, controlled release formulations, drug eluting implants and transdermal patches. Rapid technological advances and the desire to improve the efficacy and safety profile of existing medications by specific targeting to the site of action, combined with the drive to improve patient compliance, continue to fuel rapid research progress. Furthermore, the emergence of cell-based therapeutics and biopharmaceuticals such as proteins, peptides and nucleotides presents scientists with new and exciting challenges for the application of therapeutic delivery science and technology. Successful delivery strategies increasingly rely upon collaboration across a diversity of fields, including biology, chemistry, pharmacology, nanotechnology, physiology, materials science and engineering. Therapeutic Delivery recognizes the importance of this diverse research platform and encourages the publication of articles that reflect the highly interdisciplinary nature of the field. In a highly competitive industry, Therapeutic Delivery provides the busy researcher with a forum for the rapid publication of original research and critical reviews of all the latest relevant and significant developments, and focuses on how the technological, pharmacological, clinical and physiological aspects come together to successfully deliver modern therapeutics to patients. The journal delivers this essential information in concise, at-a-glance article formats that are readily accessible to the full spectrum of therapeutic delivery researchers.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
